Full Press Release Details
In this episode of the Biotech2050 podcast, Artiva’s CEO Fred Aslan discusses how lessons from the first generation of CAR-T therapies are shaping new approaches in autoimmune disease, an area where the need for more durable treatment options remains significant.
The conversation explores what CAR-T has revealed about the depth of immune intervention required to modify disease, and how Artiva is applying those insights as a clinical-stage company advancing AlloNK® in autoimmune disease, with a focus on scalability, real-world applicability, and patient access.
Watch here on YouTube